What We Offer
Our Products
CorDx Tyfast
Product Overview
CorDx Tyfast SARS-CoV-2/Flu A+B Rapid Antigen Point-of-Care Test is a lateral flow immunoassay intended for in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal swab specimens obtained from patients who are suspected of COVID-19 by their healthcare provider, within the first five days of onset of symptoms.
  • SARS-CoV-2/Flu A+B Rapid POC Combo Antigen Test
  • Simultaneous testing for acute respiratory infections caused by COVID-19, Flu A, Flu B
  • Lateral flow immunoassay
  • Covid-19: Sensitivity 89.6%; Specificity 99.8%
  • Flu A: Sensitivity 85%; Specificity 99.2%
  • Flu B: Sensitivity 87.5%; Specificity 99.8%
  • Nasal swab samples
  • Delivers results within 10 minutes
  • No equipment necessary
  • CLIA Waived Test
VISIT WEBSITE
RCS Healthcare: Our Vision
To be the leading global procurement company for the healthcare community.
LEARN MORE